Streetbeat News

Regulatory

FITB

HBAN

MTB

TROW

USB

Banking and financial stocks are trading lower due to a potential push for increased capital requirements. Fed Chair Powell stated that new rules would likely not impact smaller banks.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 7:44 pm

LFLY

UBER

Leafly (NASDAQ:LFLY) CEO Yoko Miyashita discussed the challenges of moving cannabis consumers from unlicensed to legal markets at the Benzinga Cannabis Capital Conference. Leafly recently partnered with Uber (NYSE:UBER) to launch cannabis delivery services in Canada, leveraging existing infrastructures to meet customer demands.

Portfolio Pulse from Javier Hasse

June 22, 2023 | 7:34 pm

ATVI

MSFT

SONY

Sony Interactive Entertainment CEO Jim Ryan expressed concerns about Microsoft's proposed acquisition of Activision Blizzard, stating that Sony could not risk sharing PlayStation 6 details with Activision if the buyout goes through. Ryan's remarks were made during a hearing with the U.S. Federal Trade Commission in April.

Portfolio Pulse from Franca Quarneti

June 22, 2023 | 7:21 pm

XEL

BMO Capital Markets analyst James M. Thalacker downgraded Xcel Energy Inc (NASDAQ:XEL) from Outperform to Market Perform and decreased the price target to $64 from $69 due to concerns over the lower-than-expected terms of the regulatory settlement in Colorado.

Portfolio Pulse from Lekha Gupta

June 22, 2023 | 6:58 pm

SRPT

The FDA has granted accelerated approval to Sarepta Therapeutics' gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4-5 years with a confirmed mutation in the DMD gene. Continued approval depends on further verification and description of clinical benefit in confirmatory trials. Sarepta is preparing to launch Elevidys and plans to submit a BLA supplement to expand the approved label based on the results of the confirmatory trial.

Portfolio Pulse from Vandana Singh

June 22, 2023 | 6:48 pm

SRPT

Sarepta Therapeutics has received FDA approval for ELEVIDYS, the first gene therapy to treat Duchenne Muscular Dystrophy. The one-time treatment is approved for ambulatory pediatric patients aged 4-5 years. Sarepta will host a conference call on June 22 at 4:30 p.m. ET.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 6:03 pm

FXI

SPY

President Biden stated that Secretary of State Blinken's trip to China was successful and his comment on Xi Jinping being a dictator did not undermine or complicate the US-China relationship.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 6:02 pm

BTCUSD

FTTUSD

MSTR

Bitcoin's market dominance has surpassed 51% of the total $1.1 trillion cryptocurrency market, with its market capitalization at $586.7 billion. The rise is attributed to investors considering Bitcoin as a safer alternative amid recent upheavals such as the FTX crisis and increased regulatory scrutiny in the US.

Portfolio Pulse from Murtuza Merchant

June 22, 2023 | 5:35 pm

SRPT

Sarepta Therapeutics' shares have been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 5:34 pm

GRPN

Groupon shares are trading higher despite the company announcing it is not in compliance with Nasdaq listing requirements and plans to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 4:54 pm